SCHEMBL17039697

SCHEMBL17039697

O=C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)NCCCCCC(=O)NCCOCCNC(=O)CCCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.71
PRSS1 P07477 1/20 0.71
PRSS2 P07478 1/20 0.71
PRSS3 P35030 1/20 0.71
TPSAB1 Q15661 1/20 0.71
TDP1 Q9NUW8 5/20 0.70
FOLH1 Q04609 2/20 0.69
PKM P14618 3/20 0.66
PLCD1 P51178 1/20 0.64
MEN1 O00255 1/20 0.60
ABL1 P00519 1/20 0.60
LMNA P02545 1/20 0.60
IDE P14735 1/20 0.60
MAPK1 P28482 1/20 0.60
KMT2A Q03164 1/20 0.60
RIN1 Q13671 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19017236 0.96 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL19751698 0.96 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL4968230 0.96 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL15216220 0.96 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL13497879 0.94 FOLH1 (0.76) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL13497938 0.94 F2 (0.75) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL18876785 0.94 F2 (0.65) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL13497854 0.94 PRSS1 (0.67) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL13497916 0.94 PRSS1 (0.67) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL1697052 0.94 PRSS1 (0.67) F2PRSS1PRSS2PRSS3TPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286285-B2 Modified biotin, streptavidin mutant, and usage of them SAVID THERAPEUTICS INC. (JP) 2022-03-29 US disclosed
US-11161884-B2 Modified biotin, streptavidin mutant, and usage of them SAVID THERAPEUTICS INC. (JP) 2021-11-02 US disclosed
US-11124549-B2 2021-09-21 US disclosed
EP-3842440-A2 MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM Savid Therapeutics Inc. (JP) 2021-06-30 EP disclosed
EP-3109252-B1 MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM SAVID THERAPEUTICS INC (JP) 2020-12-30 EP disclosed
US-20190382435-A1 CLEARING AGENT SAVID THERAPEUTICS INC. (JP) 2019-12-19 US disclosed
US-20170145063-A1 MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM SAVID THERAPEUTICS INC. (JP) 2017-05-25 US disclosed
WO-2015125820-A1 BIOTIN VARIANT, STREPTAVIDIN MUTANT, AND USES THEREOF サヴィッド・セラピューティックス株式会社 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145063-A1 MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM BTD, HLCS, BROX F2 1809/4885PRSS1 1862/4885PRSS2 1718/4885
US-11124549-B2 BTD, HLCS, BROX F2 2060/4885PRSS1 1346/4885PRSS2 1481/4885
US-11161884-B2 Modified biotin, streptavidin mutant, and usage of them BTD, HLCS, BROX F2 2648/4885PRSS1 1074/4885PRSS2 1145/4885
US-20190382435-A1 CLEARING AGENT MAN2B1, MAN2B2, ESYT1 F2 2467/4885PRSS1 894/4885PRSS2 851/4885
US-11286285-B2 Modified biotin, streptavidin mutant, and usage of them BTD, HLCS, BROX F2 1809/4885PRSS1 1862/4885PRSS2 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.